Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.628
Sell
RSI(14)
42.605
Neutral
STOCH(KDJ)(9,3,3)
32.643
Sell
ATR(14)
2.896
High Vlolatility
CCI(14)
-209.135
Oversold
Williams %R
74.926
Sell
TRIX(12,20)
-0.039
Sell
StochRSI(14)
0.000
Sell
IRadimed Corp
IRMD97.360USD
-1.380-1.40%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
988.20MMarket Cap
55.10P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of IRadimed Corp
Currency: USD Updated: 2026-03-27Key Insights
IRadimed Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 50 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 120.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
IRadimed Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
IRadimed Corp Highlights
StrengthsRisks
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.84% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 83.81M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 83.81M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 29.64%.
Overvalued
The company’s latest PE is 55.10, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.32M shares, decreasing 13.42% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.79K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
120.000
Target Price
+18.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of IRadimed Corp is 8.88, ranking 14 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 22.69M, representing a year-over-year increase of 17.03%, while its net profit experienced a year-over-year increase of 25.16%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.76
Operational Efficiency
8.87
Growth Potential
9.88
Shareholder Returns
7.90
IRadimed Corp's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of IRadimed Corp is 5.26, ranking 186 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 55.10, which is 14.48% below the recent high of 63.08 and 51.40% above the recent low of 26.78.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 50/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of IRadimed Corp is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 99.00, with a high of 100.00 and a low of 98.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
120.000
Target Price
+21.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
92
Total
4
Median
7
Average
Company name
Ratings
Analysts
IRadimed Corp
IRMD
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of IRadimed Corp is 6.63, ranking 94 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 104.49 and the support level at 92.74, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
99.610
Sell
MA10
100.156
Sell
MA20
100.626
Sell
MA50
100.424
Sell
MA100
96.607
Buy
MA200
81.935
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of IRadimed Corp is 5.00, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 57.54%, representing a quarter-over-quarter decrease of 1.25%. The largest institutional shareholder is The Vanguard, holding a total of 558.41K shares, representing 4.37% of shares outstanding, with 0.48% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Susi (Roger E)
BlackRock Institutional Trust Company, N.A.
Nine Ten Capital Management LLC
Copeland Capital Management, LLC
Geode Capital Management, L.L.C.
BlackRock Financial Management, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of IRadimed Corp is 7.77, ranking 30 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.10
VaR
+3.54%
240-Day Maximum Drawdown
+9.66%
240-Day Volatility
+38.30%
Return
Best Daily Return
60 days
+9.57%
120 days
+9.57%
5 years
+23.66%
Worst Daily Return
60 days
-4.77%
120 days
-4.96%
5 years
-20.08%
Sharpe Ratio
60 days
+0.11
120 days
+2.17
5 years
+0.85
Risk Assessment
Maximum Drawdown
240 days
+9.66%
3 years
+26.28%
5 years
+49.38%
Return-to-Drawdown Ratio
240 days
+9.02
3 years
+1.44
5 years
+1.05
Skewness
240 days
+1.92
3 years
+0.79
5 years
+0.75
Volatility
Realised Volatility
240 days
+38.30%
5 years
+48.05%
Standardised True Range
240 days
+2.49%
5 years
+1.90%
Downside Risk-Adjusted Return
120 days
+364.66%
240 days
+364.66%
Maximum Daily Upside Volatility
60 days
+28.74%
Maximum Daily Downside Volatility
60 days
+24.80%
Liquidity
Average Turnover Rate
60 days
+0.44%
120 days
+0.36%
5 years
--
Turnover Deviation
20 days
+31.61%
60 days
+23.14%
120 days
+2.28%
Peer Comparison
Healthcare Equipment & Supplies
IRadimed Corp
IRMD
7.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
